“I have no unique story,” Groene told the Journal Star. “This happens 99.9% of the time.” Except, of course, when people die or live with long-term effects. “I didn’t try to get contact,” Groene told KETV. “It came to me.” He added to the outlet that he feels people need to take precautions, especially if they have health conditions. He also said he “followed the rules” and plans on donating blood to help others. That’s all well and good, but we need national guidelines on mask wearing, social distancing, and resources so people can afford to stay safe and safe home. Thankfully, President-Elect Joe Biden is heading to the White House, and he isn’t waiting until he gets there to start advocating for pandemic safety. – Advertisement – – Advertisement – In speaking to KETV Omaha, he said, “I’ve been sick a lot of times. This is not different. This is not cancer. My God this hysteria.” Curious about how he thinks he got the virus? Groene told the local outlet he believes he got the virus “from someone who was wearing a mask.” He continued: “I did not wear a mask. I have not been traced that I spread to anybody.” As Groene told the outlet, he believes he got the virus while “I was at my Legislative work in Lincoln and had contact.”Obviously, there is a lot to unpack here. First, let’s talk about the idea of herd immunity, of which Groene is apparently a supporter. Then let’s go into the structural inequalities that may lead to a privileged person having a relatively better experience with the virus.- Advertisement – Herd immunity in terms of the coronavirus is a scary idea. Though Donald Trump and Dr. Scott Atlas are pushing for herd immunity as a way to tackle the virus, countless health officials are horrified at the concept. One you might recognize immediately is Dr. Anthony Fauci. Fauci has actually spoken out about Atlas in particular, noting that he has “real problems with that guy.” Which, for the mild-mannered Fauci, is some strong language.Experts have suggested that embracing herd immunity—as opposed to wearing face masks and social distancing—could lead to millions of deaths in the process. That’s horrible from the start, but especially so when we remember that the virus is disproportionately impacting people of color, older people, and people with chronic health conditions as it is. As we saw with the treatment Trump received, as well as the medical attention some high-profile Republicans, like former New Jersey Gov. Chris Christie got, medical care is, sadly, not always equal. While Groene may not have needed or received the level of care Trump received at Walter Reed National Military Medical Center, for example, we know that systemically, white people have better access to affordable, quality medical care than people of color. We also know that people of color are less likely to be taken seriously when talking about symptoms or pain management. For a white male to be relieved to have gotten the virus over with isn’t too surprising, as white men have a fair amount of privilege and resource in this nation. And even then, we know this virus doesn’t discriminate when it comes to fatalities and long-term effects. – Advertisement – The Georgia runoff is Jan. 5. Request an absentee ballot by Nov. 18. Early in-person voting starts Dec. 14. And REGISTER TO VOTE here by Dec. 7.
To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters
Facebook is implementing a monthly subscription service for content creators with the aim of helping them form solid monetization for their videos – presumably to encourage them to move from YouTube and Twitch to the social platform.Not only that, it’s introducing a searchable database full of creators that’ll allow brands to filter through and identify those in which they’d like to work alongside. This feature will require content creators to set up a portfolio to demonstrate their skills and online following in an attempt to appeal to brands.These features haven’t been developed with gaming specifically in mind, but it’s definitely relevant to those who stream or record gameplay. The database, in theory, could also enable esports organisations to find new content creators. It’d allow them to identify and connect with gamers in an easy fashion and streamlining the process.In January 2018, Facebook acquired the exclusive streaming rights for ESL One – tournaments for both Dota 2 and Counter-Strike: Global Offensive, and ESL’s CS:GO Pro League. In March 2018, the social platform also gained the broadcast rights for the Gfinity Elite Series.Esports Insider says: Twitch is thriving incredibly as of late in terms of both the amount of streamers and the amount of people watching streams, especially with Fortnite’s popularity and the growing number of esports tournaments. YouTube is still known as the hub of recorded gameplay, with content creators and competitive gameplay being uploaded on a daily basis. It’ll be a hard task for Facebook to pull them away from those platforms, but these features may help.
The Gianda Youth Development Association (GIYODA) in Kpogbahn Statutory District No.4, Grand Bassa County has congratulated Ambassador George Manneh Weah for clinching what they called ‘a volcanic victory’ over his contenders as senator-elect for Montserrado County with over 99,000 votes during the just ended Special Senatorial Elections in Monrovia.The president of GIYODA, William ‘Olu’ Diggs made the statement over the weekend, on behalf of his association in an exclusive interview with the Daily Observer in the district.According to Mr. Diggs, his association applauds Amb. Weah’s victory because of his leadership ability, knowing that the soccer icon will help to adequately steer the affairs of the country toward a better future.He prayed that God will bless Mr. Weah to succeed and achieve his vision, dream and aspiration for the presidency in the 2017 general and presidential elections.Mr. Weah deserves to be congratulated because according to Diggs, he is a sound leader who can ably represent and deliver the political goods that will transform the living standard of the people of Montserrado County.He pointed out that his association pledges its fullest support to vote Mr. Weah to victory because of his national and international experience.Diggs is requesting Mr. Weah to visit their district at his convenience because the people of the district are eager to hold discussions with him about burning issues mainly to pre-petition Amb. Weah for the presidency come 2017 general and presidential elections.‘’We are aware that you contested for the presidency twice and did not succeed, but with our strong prayer and massive support you will surely become a victor in 2017’’, the GIYODA president assured Mr. Weah.Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
PSV chief Marcel Brands has confirmed they plan to “buy” Marco van Ginkel from Chelsea.The Dutch midfielder has had two separate loan spells with PSV over the last two seasons and Brands says they’re now seeking a permanent deal.He revealed: “Marco has had a positive conversation with (coach) Phillip Cocu. I’ll now go to Chelsea for talks to see what the possibilities are. “It would be good to buy him as far as we are concerned.”A move for Tottenham striker Vincent Janssen is also on the agenda for Brands.AD says they’ll move for the former AZ star if Luuk de Jong leaves this summer.
The Next Big Question Over Amazon’s Foray Into Prescription Drugs: What Will It Do About PBMs? News outlets report on stories related to pharmaceutical pricing. Amazon’s purchase of the online pharmacy PillPack answered long-lingering questions about whether and how it would enter the prescription drug business. But it also raised another big issue: What will it do about the PBMs? Pharmacy benefit managers are the companies that stand in the middle of the nation’s supply chain for prescription drugs. They administer drug benefits on behalf of employers and labor unions, and negotiate prices and reimbursements with drug makers and pharmacies that stand on either end of those transactions. In other words, they control access to the medicines and hundreds of millions of U.S. customers who take them. (Ross, 7/16) The drug manufacturing industry’s main lobbying group is backing a big change to the way prescription drugs are priced, but it’s unclear how it would impact the industry’s business model. At first glance, it looked like PhRMA is embracing one of the Trump administration’s biggest ideas for addressing prescription drug prices — eliminating rebates that drug makers pay to pharmacy benefit managers, the middlemen that negotiate drug prices on behalf of insurance companies. But in fact, PhRMA’s idea is vague enough that it’s unclear exactly what it would do and whether it will bring down the price of drugs for patients. (Swetlitz, 7/16) J&J’s pharmaceutical sales topped analysts’ expectations despite what executives said was a continued decline in average net U.S. pricing after discounts and rebates. Chief Financial Officer Joe Wolk said on a conference call with analysts that average U.S. net pricing could decline 4% to 6% this year, after a 4.6% drop last year. J&J shares surged 4% to $128.65 in midday trading after the earnings report, though the stock is still down 7.9% year to date on investors’ concerns about slower growth in other parts of J&J’s diversified business, including consumer products. (Loftus and Prang, 7/17) Reuters: J&J Beats Quarterly Expectations On Drug Sales Surge, Shares Jump The Hill: Dem Senator Calls For ‘Permanent’ Price Cuts At Pfizer Stat: Martin Shkreli’s Drug Company Is Losing Money, Documents Show Novartis on Wednesday lowered its outlook for its Sandoz generics business, saying it expects a low-single digit decline in sales for the year. The company said earlier this year that the unit’s revenue would be broadly in line with the previous year or drop slightly. It raised its forecast for Alcon, saying it now expects mid-single digit growth in sales in 2018. The pharmaceutical giant earlier this year announced the purchase of rare-disease drugmaker AveXis Inc. for $8.7 billion, and Narasimhan has said he’s looking to focus Novartis’s gene-therapy program on cancer, neuroscience and ophthalmology. (Paton, 7/18) Bloomberg: Novartis Blockbuster Drug Rebounds, Easing Generics Pressure Sen. Tammy Baldwin (D-Wis.) on Monday called on pharmaceutical giant Pfizer to “permanently roll back prices,” days after the company said it would temporarily postpone a planned price hike. In a letter to Pfizer’s CEO Ian Read, Baldwin said the company needs to stop “playing games” with the costs of prescription drugs. Pfizer instead needs to “make a firm and clear commitment” to permanent price reductions, Baldwin wrote. (Weixel, 7/16) As a candidate and then as president, Donald Trump has had plenty to say about how drug prices are out of control and how he plans to get them down. Drug companies are “getting away with murder,” he said in January 2017, promising to save “billions” through better negotiating. On May 11, Trump called his new drug price plan “the most sweeping action in history.” And after Pfizer Inc. raised prices of many of its products this summer, he tweeted on July 9: “We will respond!” (Langreth, Koons and Gu, 7/16) Some drug companies have continued to increase prices despite growing public discontent, a move that senior equity analyst Elliot Wilbur told CNBC “makes absolutely no sense.” “It’s simply bad decision-making and terrible policy on [a drug company’s] part,” Wilbur, who focuses on pharmaceuticals at financial firm Raymond James, said Monday on “Power Lunch.” (Ell, 7/16) Novartis says net profit rose 3 percent in the second quarter amid strong growth for some of its top products, as the Swiss pharmaceuticals giant moves to spin off its Alcon eye-care business. New CEO Vas Narasimhan touted Novartis’ plans to create a “focused medicines company,” including through the Alcon spinoff announced in late June. (7/18) Stat: Hugin Punches Back Against Menendez Over Records On Drug Prices Stat: In South Dakota, Opponents Of Drug-Pricing Ballot Initiatives Claim Victory An initiative that would have attempted to cap drug prices in South Dakota was removed from the statewide ballot by a judge on Monday, the second time that a court has prevented such a measure from going before voters in the 2018 election. The ruling came after a court determined the measure’s supporters had improperly gathered some of the signatures necessary to qualify it for the ballot, according to the initiative’s biotech-backed opposition. (Facher, 7/17) Kaiser Health News: Staggering Prices Slow Insurers’ Coverage Of CAR-T Cancer Therapy This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. Stat: On Drug Pricing, PhRMA Pushes For Lower Payments To PBMs Bloomberg: Is Trump Reining In Drug Prices? We’re Keeping Track Leading trade groups for brand-name and generic drugmakers endorsed overhauling the drug rebate system as a way to address the high cost of medicines, aligning themselves with HHS Secretary Alex Azar’s bid to change industry practices around drug discounts. Pharmacy benefits managers, wholesalers, pharmacies and other intermediaries in the drug supply chain should not be paid based on a percentage of the list price of medicines but could instead get a flat fee, PhRMA said in comments on the Trump administration’s drug pricing blueprint submitted Monday. (Karlin-Smith, 7/16) The Associated Press: Swiss Drugs Giant Novartis Says Profit Up As Spinoff Looms Maryland government retirees will get financial assistance from the state to help pay for medications when their prescription drug coverage moves from a state plan to the federal Medicare Part D program next year. Gov. Larry Hogan and General Assembly leadership announced a one-year transition program in which the state will reimburse all out-of-pocket drug costs exceeding $1,500. That is the limit under the current state plan. The move to the federal prescription drug plan, which will take place Jan. 1, is part of state pension reform passed in 2011. (McDaniels, 7/16) Politico Pro: PhRMA, Generic Drug Lobby Join HHS’ Call For Overhauling Rebates Martin Shkreli’s former company is losing money, watching sales of its famously costly medicine slip while considering yet another name change. Vyera Pharmaceuticals, formerly called Turing Pharmaceuticals, lost more than $1 million in the first quarter of 2018, according to financial documents obtained by STAT. Sales, driven by the $750-a-pill Daraprim, have been on the wane over the past two years, falling more than 14 percent in 2017 and on pace to drop another 7 percent in 2018. (Garde, 7/17) CNBC: Increasing Drug Prices ‘Makes Absolutely No Sense,’ Says Analyst Johnson & Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade, and its shares rose more than 4 percent. The healthcare conglomerate also expressed confidence that last week’s finding by a Missouri jury that J&J’s talc-based products caused cancer, and an order to pay a record $4.69 billion to defendants, would not stand. (7/17) The drug industry has officially taken center stage in an increasingly bitter Senate race in New Jersey between incumbent Bob Menendez and former Celgene CEO Bob Hugin. Last week, an ad campaign excoriated Hugin for allowing Celgene to raise prices on drugs under his leadership. Now the Republican is striking back with a pharma-focused ad of his own. (Facher, 7/16) The Baltimore Sun: Maryland To Help Retirees Pay Out-Of-Pocket Medicare Drug Costs After Coverage Change Stat: Will Amazon Partner With PBMs, Or Seek To Conquer Them? Patients whose blood cancers have failed to respond to repeated rounds of chemotherapy may be candidates for a new type of gene therapy that could send their cancers into remission for years. But the two approved therapies, with price tags of hundreds of thousands of dollars, have roiled the insurance approval process, leading to delays and, in some cases, denials of coverage, clinicians and analysts say. (Andrews, 7/17) The Wall Street Journal: Johnson & Johnson’s Pharma Business Fuels Sales Growth